233 related articles for article (PubMed ID: 37165842)
1. Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions.
Kalleda N; Flace A; Altermatt P; Ingoglia G; Doucerain C; Nyffenegger N; Dürrenberger F; Manolova V
Haematologica; 2023 Oct; 108(10):2703-2714. PubMed ID: 37165842
[TBL] [Abstract][Full Text] [Related]
2. Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development.
Porter J; Taher A; Viprakasit V; Kattamis A; Coates TD; Garbowski M; Dürrenberger F; Manolova V; Richard F; Cappellini MD
Expert Rev Hematol; 2021 Jul; 14(7):633-644. PubMed ID: 34324404
[TBL] [Abstract][Full Text] [Related]
3. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.
Manolova V; Nyffenegger N; Flace A; Altermatt P; Varol A; Doucerain C; Sundstrom H; Dürrenberger F
J Clin Invest; 2019 Dec; 130(1):491-506. PubMed ID: 31638596
[TBL] [Abstract][Full Text] [Related]
4. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.
Porter JB; Cappellini MD; Kattamis A; Viprakasit V; Musallam KM; Zhu Z; Taher AT
Br J Haematol; 2017 Jan; 176(2):288-299. PubMed ID: 27917462
[TBL] [Abstract][Full Text] [Related]
5. The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.
Nyffenegger N; Flace A; Doucerain C; Dürrenberger F; Manolova V
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467196
[TBL] [Abstract][Full Text] [Related]
6. Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult β-thalassemia major.
Casu C; Chessa R; Liu A; Gupta R; Drakesmith H; Fleming R; Ginzburg YZ; MacDonald B; Rivella S
Haematologica; 2020 Jul; 105(7):1835-1844. PubMed ID: 31582543
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients.
Porter JB; Walter PB; Neumayr LD; Evans P; Bansal S; Garbowski M; Weyhmiller MG; Harmatz PR; Wood JC; Miller JL; Byrnes C; Weiss G; Seifert M; Grosse R; Grabowski D; Schmidt A; Fischer R; Nielsen P; Niemeyer C; Vichinsky E
Br J Haematol; 2014 Dec; 167(5):692-6. PubMed ID: 25209728
[TBL] [Abstract][Full Text] [Related]
8. New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD; Motta I
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
[TBL] [Abstract][Full Text] [Related]
9. Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of β-thalassemia.
Olivera J; Zhang V; Nemeth E; Ganz T
Blood Adv; 2023 Jul; 7(14):3339-3349. PubMed ID: 36995275
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis and management of iron toxicity in thalassemia.
Hershko C
Ann N Y Acad Sci; 2010 Aug; 1202():1-9. PubMed ID: 20712765
[TBL] [Abstract][Full Text] [Related]
11. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
[TBL] [Abstract][Full Text] [Related]
12. Elevated CDKN1A (P21) mediates β-thalassemia erythroid apoptosis, but its loss does not improve β-thalassemic erythropoiesis.
Liang R; Lin M; Menon V; Qiu J; Menon A; Breda L; Arif T; Rivella S; Ghaffari S
Blood Adv; 2023 Nov; 7(22):6873-6885. PubMed ID: 37672319
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of heme oxygenase ameliorates anemia and reduces iron overload in a β-thalassemia mouse model.
Garcia-Santos D; Hamdi A; Saxova Z; Fillebeen C; Pantopoulos K; Horvathova M; Ponka P
Blood; 2018 Jan; 131(2):236-246. PubMed ID: 29180398
[TBL] [Abstract][Full Text] [Related]
14. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.
Piga A; Longo F; Gamberini MR; Voskaridou E; Ricchi P; Caruso V; Pietrangelo A; Zhang X; Shetty JK; Attie KM; Tartaglione I
Ther Adv Hematol; 2022; 13():20406207221134404. PubMed ID: 36505885
[TBL] [Abstract][Full Text] [Related]
16. Transferrin therapy ameliorates disease in beta-thalassemic mice.
Li H; Rybicki AC; Suzuka SM; von Bonsdorff L; Breuer W; Hall CB; Cabantchik ZI; Bouhassira EE; Fabry ME; Ginzburg YZ
Nat Med; 2010 Feb; 16(2):177-82. PubMed ID: 20098432
[TBL] [Abstract][Full Text] [Related]
17. Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent β-thalassemia.
Di Modica SM; Tanzi E; Olivari V; Lidonnici MR; Pettinato M; Pagani A; Tiboni F; Furiosi V; Silvestri L; Ferrari G; Rivella S; Nai A
Am J Hematol; 2022 Oct; 97(10):1324-1336. PubMed ID: 36071579
[TBL] [Abstract][Full Text] [Related]
18. Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity.
Casu C; Pettinato M; Liu A; Aghajan M; Lo Presti V; Lidonnici MR; Munoz KA; O'Hara E; Olivari V; Di Modica SM; Booten S; Guo S; Neil G; Miari R; Shapir N; Zafir-Lavie I; Domev H; Ferrari G; Sitara D; Nai A; Rivella S
Blood; 2020 Oct; 136(17):1968-1979. PubMed ID: 32556142
[TBL] [Abstract][Full Text] [Related]
19. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model.
Matte A; Federti E; Kung C; Kosinski PA; Narayanaswamy R; Russo R; Federico G; Carlomagno F; Desbats MA; Salviati L; Leboeuf C; Valenti MT; Turrini F; Janin A; Yu S; Beneduce E; Ronseaux S; Iatcenko I; Dang L; Ganz T; Jung CL; Iolascon A; Brugnara C; De Franceschi L
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33822774
[TBL] [Abstract][Full Text] [Related]
20. Reversal of hemochromatosis by apotransferrin in non-transfused and transfused Hbbth3/+ (heterozygous B1/B2 globin gene deletion) mice.
Gelderman MP; Baek JH; Yalamanoglu A; Puglia M; Vallelian F; Burla B; Vostal J; Schaer DJ; Buehler PW
Haematologica; 2015 May; 100(5):611-22. PubMed ID: 25616571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
